Replies to post #154683 on Elite Pharmaceuticals Inc (ELTP)

[Couch]

What I meant was; we will have to wait and see if we load the boat a 2¢; will ELTP be worth 2¢ at 2¢.

It won't matter because as I've shown Elite isn't going to .02. Glad I loaded the boat prior to Eli 200 launch. 10 bagger coming as in the $2's are coming. And here's why.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110347712

https://clinicaltrials.gov/ct2/show/NCT02401750?term=%22Elite+Laboratories%2C+Inc%22&rank=2

Elite also announced that dosing was completed for two studies to support ELI-200 product labeling - the fed study and the withdrawal effects study. The first study is a Phase I, open-label, randomized, single-dose, three-way crossover study to compare the bioavailability of ELI-200 to the reference product under fed conditions in healthy volunteers. The second study, a safety study, is a randomized, double-blind, multiple-dose, parallel group study to evaluate the potential withdrawal effects following administration of ELI-200 versus the reference product in methadone-maintained opioid-dependent subjects. Final study results are not yet available.

A Phase III efficacy study is scheduled to begin dosing this quarter. This Phase III study is a multi-center, randomized, multiple-dose, blinded, placebo-controlled, parallel group, study to evaluate the efficacy and safety of abuse deterrent ELI-200 for the treatment of adults with moderate to severe pain following surgery. The study will enroll approximately 165 patients at five clinical sites and will begin once final FDA agreement is received for the protocol. We expect the study to begin in approximately 7 weeks and the dosing for the study to take approximately 8 weeks.

"Hydroxyzine is another generic product launched under our license to Epic," said Nasrat Hakim, President and CEO of Elite. "Elite continues to add to and grow our generic business. I am also pleased to have completed dosing for two of the ELI-200 studies requested by the FDA and we look forward to initiating the third study and reporting results in the coming months. We continue to plan for an ELI-200 filing this year."

[dr_lowenstein]

JL, what is your best guess for timing of the pps going to single digits? thanks